CWM
APLS

CIBC World Markets’s Apellis Pharmaceuticals APLS Stock Holding History

CIBC World Markets’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-1,285,300
Closed -$41M – 1845
2024
Q4 		$41M Buy
+1,285,300
New +$38.7M 0.24% 68

Other funds holding APLS

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

CIBC World Markets's APLS Position: Q1 2025 in Review

CIBC World Markets sold out of Apellis Pharmaceuticals (APLS) in Q1 2025, closing a stake of 1,285,300 shares — an estimated $41M sold.

CIBC World Markets first reported a position in APLS in Q4 2024 and held it in 1 quarter. The position peaked at $41M in Q4 2024. 255 funds tracked by Wall St. Rank hold APLS as of Q1 2025.

  • CIBC World Markets reported no remaining Apellis Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • CIBC World Markets sold 1,285,300 Apellis Pharmaceuticals shares in Q1 2025, an estimated $41M.
  • CIBC World Markets first reported a position in Apellis Pharmaceuticals in Q4 2024 and held it in 1 quarter.
  • CIBC World Markets's Apellis Pharmaceuticals position peaked at $41M in Q4 2024.
  • 255 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q1 2025.

Based on CIBC World Markets's 13F filing for Q1 2025, filed 13 May 2025.